Skip to main content

Table 2 Abstinence and other pertinent results obtained from the drop-out study

From: Non-responders in a quitline evaluation are more likely to be smokers – a drop-out and long-term follow-up study of the Swedish National Tobacco Quitline

% (n/N)

Total

Responders (both baseline and 12 months)

Non-responders (baseline but not 12 months)

p-value*

Point prevalence

45 (50/111)

54 (36/67)

32 (14/44)

.023

 - in proactive service

41 (23/56)

50 (17/34)

27 (6/22)

.091

 - in reactive service

49 (27/55)

58 (19/33)

36 (8/22)

.123

6-month continuous abstinence

38 (42/110)

49 (33/67)

21 (9/43)

.003

 - in proactive service

34 (19/56)

44 (15/34)

18 (4/22)

.045

 - in reactive service

43 (23/54)

55 (18/33)

24 (5/21)

.026

Women

75 (83/111)

72 (48/67)

79 (35/44)

.348

Age (median; q1-q3)

50; 38–58

51; 41–59

45; 34–55

.044

Pharmaceuticala use in the past 7 days

20 (22/110)

21 (14/67)

19 (8/43)

.769

Pharmaceuticala use since first call to SNTQ:

 - no

41 (45/109)

42 (28/66)

39 (17/43)

.925

 - yes, < 5 weeks

19 (21/109)

18 (12/66)

21 (9/43)

 - yes, ≥ 5 weeks

39 (43/109)

39 (26/66)

39 (17/43)

Snus use in the past 7 days

11 (12/109)

12 (8/66)

9 (4/43)

.761

Intention to quit (among still smokers):

 - action + preparation

49 (30/61)

53 (17/32)

45 (13/29)

.517

 - contempl. + precont b

51 (31/61)

47 (15/32)

55 (16/29)

  1. N = 150, response 111 (74 %). First call February 2 2009 to September 23 2010. Follow-up February to March 2013 (2 years 5 months to 4 years)
  2. *Differences between responders and non-responders were tested with the chi-square test for all variables except age which was tested with the Mann–Whitney U-test and snus use which was tested with Fisher’s exact test
  3. aNRT, Zyban®, Champix®
  4. bContempl.: contemplation. Precont.: precontemplation